Longer duration of combination antiretroviral therapy reduces the risk of hodgkin lymphoma: A cohort study of HIV-infected male veterans

Cancer Epidemiology

Volumn 38, Issue 4, 2014, Pages 386-392

  Kowalkowski, M A ^a,b,c   Mims, M A ^b   Day, R S ^d   Du, X L ^d   Chan, W ^d   Chiao, E Y ^b,c  

^a LEVINE CANCER INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Combined antiretroviral therapy; Epidemiology; HIV; Hodgkin lymphoma; Non AIDS defining cancer

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ICD-9; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VETERAN; COMPLICATION; INCIDENCE; MIDDLE AGED; REGISTER; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; VETERANS;

EID: 84904580974     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.05.009     Document Type: Article

References (33)

1. Kaplan J.E., Hanson D., Dworkin M.S., Frederick T., Bertolli J., Lindegren M.L., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30(Suppl. 1):S5-S14.
2. Herida M., Mary-Krause M., Kaphan R., Cadranel J., Poizot-Martin I., Rabaud C., et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003, 21(18):3447-3453.
3. Engels E.A., Pfeiffer R.M., Goedert J.J., Virgo P., McNeel T.S., Scoppa S.M., et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006, 20(12):1645-1654.
4. Shiels M.S., Pfeiffer R.M., Gail M.H., Hall H.I., Li J., Chaturvedi A.K., et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011, 103(9):753-762.
5. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370(9581):59-67.
6. Shiels M.S., Cole S.R., Kirk G.D., Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009, 52(5):611-622.
7. Engels E.A. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009, 23(8):875-885.
8. Martis N., Mounier N. Hodgkin lymphoma in patients with HIV infection: a review. Curr Hematol Malig Rep 2012, 7(3):228-234.
9. Gills J.J., Lopiccolo J., Dennis P.A. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy 2008, 4(1):107-109.
10. Jiang W., Mikochik P.J., Ra J.H., Lei H., Flaherty K.T., Winkler J.D., et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 2007, 67(3):1221-1227.
11. Sciamanna I., Landriscina M., Pittoggi C., Quirino M., Mearelli C., Beraldi R., et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005, 24(24):3923-3931.
12. Landriscina M., Bagala C., Piscazzi A., Schinzari G., Quirino M., Fabiano A., et al. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate 2009, 69(7):744-754.
13. Powles T., Robinson D., Stebbing J., Shamash J., Nelson M., Gazzard B., et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009, 27(6):884-890.
14. Chao C., Leyden W.A., Xu L., Horberg M.A., Klein D., Towner W.J., et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS 2012, 26(17):2223-2231.
15. Bohlius J., Schmidlin K., Boue F., Fatkenheuer G., May M., Caro-Murillo A.M., et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes. Blood 2011, 117(23):6100-6108.
16. Guiguet M., Boue F., Cadranel J., Lang J.M., Rosenthal E., Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009, 10(12):1152-1159.
17. Backus L., Mole L., Chang S., Deyton L. The immunology case registry. J Clin Epidemiol 2001, 54(Suppl. 1):S12-S15.
18. Backus L.I., Gavrilov S., Loomis T.P., Halloran J.P., Phillips B.R., Belperio P.S., et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009, 16(6):775-783.
19. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
20. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45(6):613-619.
21. Dolcetti R., Boiocchi M., Gloghini A., Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 2001, 37(10):1276-1287.
22. Kutok J.L., Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006, 1:375-404.
23. Jaffe H.W., De Stavola B.L., Carpenter L.M., Porter K., Cox D.R. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS 2011, 25(11):1395-1403. the Cascade Collaboration.
24. Douek D.C., Roederer M., Koup R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009, 60:471-484.
25. Moir S., Malaspina A., Ho J., Wang W., Dipoto A.C., O'Shea M.A., et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008, 197(4):572-579.
26. French M.A., Lenzo N., John M., Mallal S.A., McKinnon E.J., James I.R., et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000, 1(2):107-115.
27. Lawn S.D., Bekker L.G., Miller R.F. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005, 5(6):361-373.
28. Gills J.J., Lopiccolo J., Tsurutani J., Shoemaker R.H., Best C.J., Abu-Asab M.S., et al. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007, 13(17):5183-5194.
29. Landriscina M., Altamura S.A., Roca L., Gigante M., Piscazzi A., Cavalcanti E., et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer 2008, 122(12):2842-2850.
30. Martin S.L. Ribonucleoprotein particles with LINE-1 RNA in mouse embryonal carcinoma cells. Mol Cell Biol 1991, 11(9):4804-4807.
31. Landriscina M., Fabiano A., Altamura S., Bagala C., Piscazzi A., Cassano A., et al. Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab 2005, 90(10):5663-5671.
32. Kramer J.R., Giordano T.P., Souchek J., Richardson P., Hwang L.Y., El-Serag H.B. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005, 100(1):56-63.
33. Chiao E.Y., Giordano T.P., Richardson P., El-Serag H.B. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008, 26(3):474-479.